Literature DB >> 12932144

Renieramycin J, a highly cytotoxic tetrahydroisoquinoline alkaloid, from a marine sponge Neopetrosia sp..

Naoya Oku1, Shigeki Matsunaga, Rob W M van Soest, Nobuhiro Fusetani.   

Abstract

Renieramycin J (1), a new tetrahydroisoquinoline alkaloid, has been isolated from a marine sponge Neopetrosia sp. as a potent cytotoxin that induced morphological changes in 3Y1 cells. Such changes are characteristic of RNA and/or protein synthesis inhibitors. The structure of 1 including the absolute stereochemistry was determined by spectroscopic and chemical methods.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12932144     DOI: 10.1021/np030092g

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  19 in total

1.  PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity.

Authors:  J F M Leal; M Martínez-Díez; V García-Hernández; V Moneo; A Domingo; J A Bueren-Calabuig; A Negri; F Gago; M J Guillén-Navarro; P Avilés; C Cuevas; L F García-Fernández; C M Galmarini
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  Bioactive Compounds from Marine Heterobranchs.

Authors:  Conxita Avila; Carlos Angulo-Preckler
Journal:  Mar Drugs       Date:  2020-12-21       Impact factor: 5.118

3.  Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®)).

Authors:  Mario González-Sales; Belén Valenzuela; Carlos Pérez-Ruixo; Carlos Fernández Teruel; Bernardo Miguel-Lillo; Arturo Soto-Matos; Juan Jose Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

Review 4.  Marine anticancer drugs and their relevant targets: a treasure from the ocean.

Authors:  Manisha Nigam; Hafiz Ansar Rasul Suleria; Mohammad Hosein Farzaei; Abhay Prakash Mishra
Journal:  Daru       Date:  2019-06-05       Impact factor: 3.117

5.  Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.

Authors:  Christophe Massard; Jane Margetts; Nadia Amellal; Yvette Drew; Ratislav Bahleda; Peter Stephens; Peter Stevens; Jean Pierre Armand; Hilary Calvert; Jean Charles Soria; Cinthya Coronado; Carmen Kahatt; Vicente Alfaro; Mariano Siguero; Carlos Fernández-Teruel; Ruth Plummer
Journal:  Invest New Drugs       Date:  2012-06-12       Impact factor: 3.850

6.  An Efficient DNA Extraction for a Blue Xestospongia sp. Sponge and Its Associated Microorganisms Containing Cytotoxic Substances.

Authors:  Thaniwan Cheun-Arom; Taksina Chuanasa
Journal:  Mar Biotechnol (NY)       Date:  2021-10-29       Impact factor: 3.619

7.  Phase II study of weekly PM00104 (ZALYPSIS(®)) in patients with pretreated advanced/metastatic endometrial or cervical cancer.

Authors:  Lainie P Martin; Carolyn Krasner; Teresa Rutledge; Manuel Luque Ibañes; Eva M Fernández-García; Carmen Kahatt; Mariano Siguero Gómez; Scott McMeekin
Journal:  Med Oncol       Date:  2013-06-15       Impact factor: 3.064

8.  Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors.

Authors:  Ramón Salazar; Antonio Calles; Marta Gil; Ignacio Durán; Margarita García; Manuel Hidalgo; Cinthya Coronado; Vicente Alfaro; Mariano Siguero; Carlos Fernández-Teruel; Raquel Prados; Emiliano Calvo
Journal:  Invest New Drugs       Date:  2014-02-19       Impact factor: 3.850

9.  The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer.

Authors:  Julius Semenas; Andreas Hedblom; Regina R Miftakhova; Martuza Sarwar; Rikard Larsson; Liliya Shcherbina; Martin E Johansson; Pirkko Härkönen; Olov Sterner; Jenny L Persson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-28       Impact factor: 11.205

10.  First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours.

Authors:  T A Yap; H Cortes-Funes; H Shaw; R Rodriguez; D Olmos; R Lal; P C Fong; D S Tan; D Harris; J Capdevila; C Coronado; V Alfaro; A Soto-Matos; C Fernández-Teruel; M Siguero; J M Tabernero; L Paz-Ares; J S de Bono; J A López-Martin
Journal:  Br J Cancer       Date:  2012-04-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.